Shanghai, July 23, 2024 -- Luye Pharma Group has announced that its subsidiary, Shenzhen Luye, will receive a strategic investment of up to RMB 1.6 billion from Shenzhen Luye Private Equity Investment Fund.
Nanjing Luye, a wholly-owned subsidiary of Luye Pharma, is a leading oncology company renowned for its technological expertise. With years of independent R&D and commercial operations, Nanjing Luye has developed a portfolio of differentiated products with significant clinical value, including Lipusu®, Tiandixin®, Tiandida®, and Zepzelca®. To leverage this growing portfolio fully, Luye Pharma has established Shenzhen Luye as a controlling entity of Nanjing Luye, aiming to integrate resources and maximize the value of its assets. This strategic move is expected to drive Shenzhen Luye’s growth and elevate its business strategy.
The Shenzhen Municipal Government has prioritized the development of the city’s innovative pharmaceutical industry in recent years. Through supportive policies, it has fostered in-depth collaboration between leading pharmaceutical companies and financial investors, propelling the development of innovative pharmaceuticals in Shenzhen. With industry funds backing it, Shenzhen Luye is poised to become a new growth driver for Luye Pharma.
The investment announced today is expected to benefit Luye Pharma in a number of ways and drive the high-quality growth of Shenzhen Luye. It will provide the Group with substantial cash flow, significantly improving its financial structure and profitability. It will also enable the Group to focus its R&D on original innovations, such as best-in-class and first-in-class products, by strengthening technological partnerships and attracting top local R&D talent. In addition, Luye Pharma plans to integrate its platforms and resources to transform its marketing model across the Greater Bay Area and nationwide, and to support Shenzhen Luye in marketing, medical affairs, market access and sales, thereby enhancing its overall competitiveness.
Shenzhen Luye Private Equity Investment Fund is managed by Shenzhen Investment Holdings Capital Co., Ltd., which is wholly owned by Shenzhen Investment Holdings Co., Ltd. and the ultimate beneficial owner of which is Shenzhen Municipal People’s Government State-owned Assets Supervision and Administration Commission.
Yang Rongbing, President of Luye Pharma Group said: “This strategic investment aligns perfectly with our business strategy. It signifies the investor’s confidence in our R&D capabilities and market value, and marks a milestone in our collaborative development. This investment will enhance our asset quality and operational efficiency, driving high-quality business growth. Ultimately, it will enable us to better serve patients and create greater value for our shareholders.”
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies, and is also actively making strategic developments in the fields of cell therapies and gene therapies.
Luye Pharma is developing a global supply chain of 8 manufacturing sites built up around the world, with GMP quality management and control systems established in line with international standards. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets -- China, the U.S., Europe and Japan, as well as in fast growing emerging markets.
Shanghai, July 23, 2024 -- Luye Pharma Group has announced that its subsidiary, Shenzhen Luye, will receive a strategic investment of up to RMB 1.6 billion from Shenzhen Luye Private Equity Investment Fund.
Nanjing Luye, a wholly-owned subsidiary of Luye Pharma, is a leading oncology company renowned for its technological expertise. With years of independent R&D and commercial operations, Nanjing Luye has developed a portfolio of differentiated products with significant clinical value, including Lipusu®, Tiandixin®, Tiandida®, and Zepzelca®. To leverage this growing portfolio fully, Luye Pharma has established Shenzhen Luye as a controlling entity of Nanjing Luye, aiming to integrate resources and maximize the value of its assets. This strategic move is expected to drive Shenzhen Luye’s growth and elevate its business strategy.
The Shenzhen Municipal Government has prioritized the development of the city’s innovative pharmaceutical industry in recent years. Through supportive policies, it has fostered in-depth collaboration between leading pharmaceutical companies and financial investors, propelling the development of innovative pharmaceuticals in Shenzhen. With industry funds backing it, Shenzhen Luye is poised to become a new growth driver for Luye Pharma.
The investment announced today is expected to benefit Luye Pharma in a number of ways and drive the high-quality growth of Shenzhen Luye. It will provide the Group with substantial cash flow, significantly improving its financial structure and profitability. It will also enable the Group to focus its R&D on original innovations, such as best-in-class and first-in-class products, by strengthening technological partnerships and attracting top local R&D talent. In addition, Luye Pharma plans to integrate its platforms and resources to transform its marketing model across the Greater Bay Area and nationwide, and to support Shenzhen Luye in marketing, medical affairs, market access and sales, thereby enhancing its overall competitiveness.
Shenzhen Luye Private Equity Investment Fund is managed by Shenzhen Investment Holdings Capital Co., Ltd., which is wholly owned by Shenzhen Investment Holdings Co., Ltd. and the ultimate beneficial owner of which is Shenzhen Municipal People’s Government State-owned Assets Supervision and Administration Commission.
Yang Rongbing, President of Luye Pharma Group said: “This strategic investment aligns perfectly with our business strategy. It signifies the investor’s confidence in our R&D capabilities and market value, and marks a milestone in our collaborative development. This investment will enhance our asset quality and operational efficiency, driving high-quality business growth. Ultimately, it will enable us to better serve patients and create greater value for our shareholders.”
About Luye Pharma Group
Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies, and is also actively making strategic developments in the fields of cell therapies and gene therapies.
Luye Pharma is developing a global supply chain of 8 manufacturing sites built up around the world, with GMP quality management and control systems established in line with international standards. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets -- China, the U.S., Europe and Japan, as well as in fast growing emerging markets.
